STOCKHOLM, Oct. 19, 2025 /PRNewswire/ — Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today a revised full year outlook for 2025 in response to recent developments. As a result of this announcement, Sobi will make adjustments […]
Tag: Swedish Orphan Biovitrum AB
US FDA grants Priority Review to Sobi’s supplemental Biologics Licence Application (sBLA) for Gamifant® (emapalumab-lzsg)
STOCKHOLM, Feb. 27, 2025 /PRNewswire/ — Sobi® (STO: SOBI), today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Gamifant® (emapalumab-Izsg) for use in adult and […]
EMA validates indication extension application for Aspaveli® for treatment of C3G and primary IC-MPGN
STOCKHOLM, Feb. 20, 2025 /PRNewswire/ — Sobi® and Apellis Pharmaceuticals today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 glomerulopathy (C3G) and primary immune […]
Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)
STOCKHOLM, Nov. 11, 2024 /PRNewswire/ — The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Extraordinary General Meeting (the “Meeting“), to be held on Wednesday, 11 December 2024 […]
Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)
STOCKHOLM, Nov. 11, 2024 /PRNewswire/ — The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Extraordinary General Meeting (the “Meeting“), to be held on Wednesday, 11 December 2024 […]
